Developer docs
API playgroundTry for free, no card

Search company profiles

Bluejay Therapeutics

Full company profile

uuid0000798

Namestring
Bluejay Therapeutics
Legal namestring
Bluejay Therapeutics, Inc.
Websiteurl
bluejaytx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Bluejay Therapeutics was a privately-held clinical-stage biopharmaceutical company founded in 2019 and headquartered in San Mateo, California, focused on developing treatments for viral hepatitis and other serious liver diseases. The company's pipeline centered on brelovitug, a fully human monoclonal antibody targeting chronic hepatitis delta virus (HDV) — the most severe form of viral hepatitis — which received both FDA Breakthrough Therapy designation and EMA PRIME designation. Brelovitug demonstrated 100% HDV RNA response in Phase 2 trials and was advancing through the Phase 3 AZURE registrational program with topline data expected in H2 2026. Bluejay's secondary program was an HBsAg inhibitor targeting chronic hepatitis B virus (HBV), intended as part of a combination approach to achieve functional cure for chronic HBV infection. Peak sales potential for brelovitug was estimated at over $750 million.

Bluejay operated as a pre-commercial R&D entity with no product revenue. Its business model relied on venture capital funding and clinical development execution. Across three equity rounds (2021 seed ~$19M, $41M Series B in August 2022 led by Arkin Bio Ventures, and $182M Series C in May 2024 led by Frazier Life Sciences), the company raised approximately $242 million from a syndicate including Novo Holdings, RA Capital Management, T. Rowe Price, Wellington Management, HBM Healthcare Investments, and RiverVest. The company was led by Founder, CEO, and Chairman Dr. Keting Chu, an experienced biotech executive whose prior roles included VP of Biology and Head of R&D at Five Prime Therapeutics and Head of Immunotherapy and Antibody Therapeutics at Chiron Corporation.

In January 2026, Mirum Pharmaceuticals completed its acquisition of Bluejay Therapeutics for up to $820 million, comprising $620 million upfront and up to $200 million in potential milestone payments. The transaction added brelovitug to Mirum's rare liver disease commercial portfolio, transferring future commercialization, distribution, and revenue mechanics to Mirum's established hepatology infrastructure. Bluejay now operates as a wholly-owned subsidiary of Mirum Pharmaceuticals.

Short descriptiontext

Bluejay Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for viral hepatitis, with lead asset brelovitug in Phase 3 trials for chronic hepatitis delta virus. Acquired by Mirum Pharmaceuticals in January 2026 for up to $820 million.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
hepatitis therapeutics, monoclonal antibodies, viral hepatitis treatment, infectious disease drugs, biopharmaceutical development
Industry1 code
PRIMARYHLAKAGAC
Hepatology (Viral Hepatitis)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals — Hepatitis Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Bluejay Therapeutics develops biologic therapeutics for chronic viral hepatitis, with its lead asset brelovitug being a late-stage fully human monoclonal antibody targeting chronic hepatitis delta virus (HDV) that has received FDA Breakthrough Therapy and EMA PRIME designations. The company also pursues a functional cure for chronic hepatitis B virus (HBV) through an HBsAg inhibitor program combined with monoclonal antibody approaches.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 100% HDV RNA response demonstrated in Phase 2 trials
+1 more record
Product overview1 text field

Bluejay Therapeutics was a biotech company focused on viral hepatitis and serious liver diseases. Its lead product was brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus (HDV), which received FDA Breakthrough Therapy and EMA PRIME designations. The company was also developing an HBsAg inhibitor as part of its hepatitis B virus programs. Bluejay was acquired by Mirum Pharmaceuticals in January 2026 for up to $820 million.

Product and service2 records
1Brelovitug
CategoryHepatitis D (HDV) therapeutic — monoclonal antibody
Description

A late-stage fully human monoclonal antibody targeting chronic hepatitis delta virus (HDV), with FDA Breakthrough Therapy and EMA PRIME designations. Demonstrated 100% HDV RNA response in Phase 2 trials and is being developed for the treatment of patients with chronic hepatitis D infection — the most severe form of viral hepatitis.

2HBsAg Inhibitor
CategoryHepatitis B (HBV) therapeutic — small-molecule inhibitor
Description

An HBsAg (hepatitis B surface antigen) inhibitor program targeting hepatitis B virus (HBV), part of Bluejay Therapeutics' pipeline for developing a functional cure for chronic HBV infection, intended for use in combination with monoclonal antibody approaches.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Mirum Pharmaceuticals acquired Bluejay Therapeutics for up to $820 million (including $620M upfront and up to $200M in milestone payments). The acquisition added brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus with FDA Breakthrough Therapy and EMA PRIME designations, to Mirum's rare liver disease portfolio. The deal was completed in January 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immunology company developing therapies for chronic hepatitis B and hepatitis D, including monoclonal antibody and siRNA approaches. Direct competitor to Bluejay's brelovitug in chronic HDV and HBV functional cure strategies.

TypeDirect peer
Description

Biotech focused on chronic HBV functional cure using RNAi (AB-729) and oral capsid inhibitor approaches. Directly comparable to Bluejay in target indication (chronic HBV) and combination cure strategy.

TypeBroad incumbent
Description

Major biopharmaceutical company with established HBV franchise (Vemlidy/tenofovir) and active R&D efforts toward functional cure. Larger incumbent overlapping in chronic hepatitis B market.

TypeDirect peer
Description

China- and US-based biotech developing siRNA, monoclonal antibody, and combination therapies for chronic HBV, including functional cure strategies. Directly comparable target indication and modality mix.

TypeBroad incumbent
Description

Global biopharma with diagnostics and therapeutics presence in viral hepatitis, including HBV programs. Broad incumbent with overlapping capability in hepatology indications.

TypeBroad incumbent
Description

Global biopharma with established presence in liver and infectious disease therapeutics, including chronic HBV pipeline investments. Broad incumbent overlapping in viral hepatitis.

TypeDirect peer
Description

Clinical-stage biotech developing a portfolio of HBV core inhibitors and other small molecules aimed at functional cure of chronic hepatitis B. Directly comparable pipeline and indication overlap.

TypeDirect peer
Description

Developer of oligonucleotide and small molecule therapies for chronic hepatitis B and hepatitis D, with multiple programs targeting functional cure. Comparable preclinical/clinical pipeline and target indications.

TypeBroad incumbent
Description

Global biopharma with hepatitis R&D programs including TLR agonists and entry inhibitors for chronic HBV. Broad incumbent with overlapping hepatology therapeutic interests.

TypeBroad incumbent
Description

Diversified biopharma with hepatitis programs through Janssen, including investigational therapies for chronic HBV and HDV. Larger incumbent with hepatology footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bluejay Therapeutics

Biopharmaceuticals — Hepatitis Therapeuticsbluejaytx.com

Bluejay Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for viral hepatitis, with lead asset brelovitug in Phase 3 trials for chronic hepatitis delta virus. Acquired by Mirum Pharmaceuticals in January 2026 for up to $820 million.

What Bluejay Therapeutics does

Bluejay Therapeutics was a privately-held clinical-stage biopharmaceutical company founded in 2019 and headquartered in San Mateo, California, focused on developing treatments for viral hepatitis and other serious liver diseases. The company's pipeline centered on brelovitug, a fully human monoclonal antibody targeting chronic hepatitis delta virus (HDV) — the most severe form of viral hepatitis — which received both FDA Breakthrough Therapy designation and EMA PRIME designation. Brelovitug demonstrated 100% HDV RNA response in Phase 2 trials and was advancing through the Phase 3 AZURE registrational program with topline data expected in H2 2026. Bluejay's secondary program was an HBsAg inhibitor targeting chronic hepatitis B virus (HBV), intended as part of a combination approach to achieve functional cure for chronic HBV infection. Peak sales potential for brelovitug was estimated at over $750 million.

Bluejay operated as a pre-commercial R&D entity with no product revenue. Its business model relied on venture capital funding and clinical development execution. Across three equity rounds (2021 seed ~$19M, $41M Series B in August 2022 led by Arkin Bio Ventures, and $182M Series C in May 2024 led by Frazier Life Sciences), the company raised approximately $242 million from a syndicate including Novo Holdings, RA Capital Management, T. Rowe Price, Wellington Management, HBM Healthcare Investments, and RiverVest. The company was led by Founder, CEO, and Chairman Dr. Keting Chu, an experienced biotech executive whose prior roles included VP of Biology and Head of R&D at Five Prime Therapeutics and Head of Immunotherapy and Antibody Therapeutics at Chiron Corporation.

In January 2026, Mirum Pharmaceuticals completed its acquisition of Bluejay Therapeutics for up to $820 million, comprising $620 million upfront and up to $200 million in potential milestone payments. The transaction added brelovitug to Mirum's rare liver disease commercial portfolio, transferring future commercialization, distribution, and revenue mechanics to Mirum's established hepatology infrastructure. Bluejay now operates as a wholly-owned subsidiary of Mirum Pharmaceuticals.

Bluejay Therapeutics firmographics

Firmographics
Name
Bluejay Therapeutics
Legal name
Bluejay Therapeutics, Inc.
Website
https://bluejaytx.com
Company type
Private
Founded year
2020
Operating status
Acquired
Headcount range
1–10 employees
Short description
Bluejay Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for viral hepatitis, with lead asset brelovitug in Phase 3 trials for chronic hepatitis delta virus. Acquired by Mirum Pharmaceuticals in January 2026 for up to $820 million.
Ownership category
akta.pro rank

Bluejay Therapeutics industry classification

Industry
Product category
Biopharmaceuticals — Hepatitis Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAKAGAC
Hepatology (Viral Hepatitis)

Keywords

  • Hepatitis therapeutics
  • Monoclonal antibodies
  • Viral hepatitis treatment
  • Infectious disease drugs
  • Biopharmaceutical development

Where Bluejay Therapeutics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Bluejay Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Bluejay Therapeutics product offering

Product offering

Core offering

Bluejay Therapeutics develops biologic therapeutics for chronic viral hepatitis, with its lead asset brelovitug being a late-stage fully human monoclonal antibody targeting chronic hepatitis delta virus (HDV) that has received FDA Breakthrough Therapy and EMA PRIME designations. The company also pursues a functional cure for chronic hepatitis B virus (HBV) through an HBsAg inhibitor program combined with monoclonal antibody approaches.

Product overview

Bluejay Therapeutics was a biotech company focused on viral hepatitis and serious liver diseases. Its lead product was brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus (HDV), which received FDA Breakthrough Therapy and EMA PRIME designations. The company was also developing an HBsAg inhibitor as part of its hepatitis B virus programs. Bluejay was acquired by Mirum Pharmaceuticals in January 2026 for up to $820 million.

Differentiator

Problem solved

Functional benefit

Products and services

  • Brelovitug A late-stage fully human monoclonal antibody targeting chronic hepatitis delta virus (HDV), with FDA Breakthrough Therapy and EMA PRIME designations. Demonstrated 100% HDV RNA response in Phase 2 trials and is being developed for the treatment of patients with chronic hepatitis D infection — the most severe form of viral hepatitis.
  • HBsAg Inhibitor An HBsAg (hepatitis B surface antigen) inhibitor program targeting hepatitis B virus (HBV), part of Bluejay Therapeutics' pipeline for developing a functional cure for chronic HBV infection, intended for use in combination with monoclonal antibody approaches.

Quantifiable outcome

  • 100% HDV RNA response demonstrated in Phase 2 trials
  • +1 more outcomes

Companies that use Bluejay Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Bluejay Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Bluejay Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Mirum PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2026Mirum Pharmaceuticals acquired Bluejay Therapeutics for up to $820 million (including $620M upfront and up to $200M in milestone payments). The acquisition added brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus with FDA Breakthrough Therapy and EMA PRIME designations, to Mirum's rare liver disease portfolio. The deal was completed in January 2026.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Bluejay Therapeutics competitors and assessment

Company assessment

Direct peers

  • Vir Biotechnology: Clinical-stage immunology company developing therapies for chronic hepatitis B and hepatitis D, including monoclonal antibody and siRNA approaches. Direct competitor to Bluejay's brelovitug in chronic HDV and HBV functional cure strategies.
  • Arbutus Biopharma: Biotech focused on chronic HBV functional cure using RNAi (AB-729) and oral capsid inhibitor approaches. Directly comparable to Bluejay in target indication (chronic HBV) and combination cure strategy.
  • Brii Biosciences: China- and US-based biotech developing siRNA, monoclonal antibody, and combination therapies for chronic HBV, including functional cure strategies. Directly comparable target indication and modality mix.
  • Assembly Biosciences: Clinical-stage biotech developing a portfolio of HBV core inhibitors and other small molecules aimed at functional cure of chronic hepatitis B. Directly comparable pipeline and indication overlap.
  • Aligos Therapeutics: Developer of oligonucleotide and small molecule therapies for chronic hepatitis B and hepatitis D, with multiple programs targeting functional cure. Comparable preclinical/clinical pipeline and target indications.

Broad incumbents

  • Gilead Sciences: Major biopharmaceutical company with established HBV franchise (Vemlidy/tenofovir) and active R&D efforts toward functional cure. Larger incumbent overlapping in chronic hepatitis B market.
  • Roche: Global biopharma with diagnostics and therapeutics presence in viral hepatitis, including HBV programs. Broad incumbent with overlapping capability in hepatology indications.
  • AstraZeneca: Global biopharma with established presence in liver and infectious disease therapeutics, including chronic HBV pipeline investments. Broad incumbent overlapping in viral hepatitis.
  • GlaxoSmithKline: Global biopharma with hepatitis R&D programs including TLR agonists and entry inhibitors for chronic HBV. Broad incumbent with overlapping hepatology therapeutic interests.
  • Johnson & Johnson: Diversified biopharma with hepatitis programs through Janssen, including investigational therapies for chronic HBV and HDV. Larger incumbent with hepatology footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Bluejay Therapeutics social profiles

Digital presence

Bluejay Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bluejay Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Bluejay Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bluejay Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bluejay Therapeutics

What does Bluejay Therapeutics do?

Bluejay Therapeutics develops biologic therapeutics for chronic viral hepatitis, with its lead asset brelovitug being a late-stage fully human monoclonal antibody targeting chronic hepatitis delta virus (HDV) that has received FDA Breakthrough Therapy and EMA PRIME designations. The company also pursues a functional cure for chronic hepatitis B virus (HBV) through an HBsAg inhibitor program combined with monoclonal antibody approaches.

Is Bluejay Therapeutics a public or private company?

Bluejay Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Bluejay Therapeutics founded?

Bluejay Therapeutics was founded in 2020. It employs 1 to 10 people.

Where is Bluejay Therapeutics based?

Bluejay Therapeutics is headquartered in San Francisco, United States, in the North America region.

Who are Bluejay Therapeutics's main competitors?

Direct peers on record are Vir Biotechnology, Arbutus Biopharma, Brii Biosciences, Assembly Biosciences and Aligos Therapeutics. Broad incumbents are Gilead Sciences, Roche, AstraZeneca, GlaxoSmithKline and Johnson & Johnson.

Does Bluejay Therapeutics have an API?

No public API is recorded for Bluejay Therapeutics.

What industry is Bluejay Therapeutics in?

Bluejay Therapeutics's product category is Biopharmaceuticals — Hepatitis Therapeutics. Its primary akta.pro industry code is HLAKAGAC, Hepatology (Viral Hepatitis). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogMirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateMirum Pharmaceuticals reported Q1 2026 net product sales of $159.9 million and raised its 2026 guidance to $660-680 million. The company also announced in-licensing of zilurgisertib for FOP with an FDA Priority Review date of September 26, 2026.The Motley Fool2 Under-the-Radar Biotech Stocks Worth Buying for the Long TermThe article is an investment analysis recommending Vertex Pharmaceuticals and Mirum Pharmaceuticals as under-the-radar biotech stocks worth buying for the long term. Vertex reported record 2025 annual revenue of $12 billion, up 9%, and received FDA approval on April 1 to expand its cystic fibrosis therapies Trikafta and Alyftrek to 95% of all U.S. CF patients, solidifying its market dominance. Mirum reported 2025 revenue of $521.3 million, up 54%, completed its $820 million acquisition of Bluejay Therapeutics in January to add the Breakthrough Therapy-designated drug brelovitug to its pipeline, and forecasts 2026 product sales of $630 million to $650 million.The Motley Fool2 Under-the-Radar Biotech Stocks Worth Buying for the Long TermMirum Pharmaceuticals reported 2025 revenue of $521.3 million, up 54%, driven by Livmarli, and forecasts 2026 sales of $630-650 million. Vertex Pharmaceuticals reported record 2025 revenue of $12 billion and expanded CF therapy labels to 95% of U.S. patients. Both companies are positioned for long-term growth in rare disease markets.Investing.comMirum Pharma CEO Peetz sells $941k in shares By Investing.comMirum Pharmaceuticals CEO Christopher Peetz sold 9,108 shares for approximately $941,000 on February 2, 2026, with the transaction executed to cover tax withholding obligations tied to the vesting of restricted stock units. The biopharmaceutical company, valued at $6.3 billion and trading near its 52-week high, reported preliminary 2025 net product sales of approximately $520 million, exceeding prior guidance, and has projected 2026 global net product sales between $630 million and $650 million. Mirum also completed its acquisition of Bluejay Therapeutics, adding the late-stage drug candidate brelovitug to its portfolio.BNNHot Picks: Small-cap pharma stocks in focus as key drug approvals nearBNN Bloomberg interviewed Terry Smith of Emerald Advisers on February 4, 2026, highlighting three small-cap pharmaceutical companies with upcoming catalysts as investment opportunities. United Therapeutics could double its sales if Phase 3 data for Tyvaso in idiopathic pulmonary fibrosis succeeds in the next 2-3 months, potentially generating $3-4 billion in peak sales. Axsome's drug Auvelity is growing 50% annually in major depressive disorder and awaits FDA approval for Alzheimer's disease agitation, while Mirum's pipeline of liver drugs and recent Bluejay Therapeutics acquisition could deliver multiple Phase 3 readouts over the next year.FierceBiotechHow Mirum is Advancing Rare Disease Care Through Strategic M&AMirum Pharmaceuticals is expanding its rare disease portfolio through targeted M&A, notably by acquiring Bluejay Therapeutics, which has a leading asset in hepatitis delta virus (HDV). The company is focusing on late-stage pipeline development with multiple clinical catalysts planned over the next 18 months, leveraging its established infrastructure.PR NewswireChronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsightThe market for chronic hepatitis D is expected to grow significantly from 2025 to 2034, driven by emerging therapies such as Brelovitug and Tobevibart + Elebsiran. Leading companies like Bluejay Therapeutics and Vir Biotechnology are developing new treatments amid increasing global disease burden and improved diagnostics.Investing.comHeron Patrick J buys Mirum Pharmaceuticals shares worth $8.99m By Investing.comDirector Patrick J. Heron purchased 131,425 shares of Mirum Pharmaceuticals at $68.48 per share for approximately $9 million on January 23, 2026, with additional indirect acquisition of shares through Frazier Life Sciences X, L.P. in connection with the merger of Bluejay Therapeutics. Mirum Pharmaceuticals reported preliminary 2025 net product sales of approximately $520 million, exceeding guidance, and projected 2026 sales of $630-650 million, representing potential growth of up to 25% year-over-year. Multiple analysts, including H.C. Wainwright, Citizens, and Baird, raised their price targets on Mirum following the company's strong performance and its acquisition of brelovitug from Bluejay Therapeutics.FinSMEsMirum Pharmaceuticals Completes Acquisition of Bluejay TherapeuticsMirum Pharmaceuticals completed its acquisition of Bluejay Therapeutics, paying with cash, stock, and potential milestone payments. The deal included $268.5M in financing proceeds. Mirum gained worldwide rights to brelovitug, a late-stage HDV antibody, with topline data expected in H2 2026.Business Wire BlogMirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare DiseaseMirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, gaining worldwide rights to brelovitug, a late-stage fully human monoclonal antibody for chronic hepatitis delta virus (HDV) that has received FDA Breakthrough Therapy and EMA PRIME designations. The deal involved a combination of cash and Mirum common stock with potential tiered sales-based milestone payments, and was accompanied by a $268.5 million private placement financing. Brelovitug is currently in the global AZURE Phase 3 registrational program with topline data expected in the second half of 2026 and a potential BLA submission and launch in 2027.